Drawing First Blood
induction. The trial findings suggest one of two things:
Transplant patients treated with CPX-351 were less sick
and didn’t die as often from HCT-related complications,
or – more likely – the patients who underwent HCT after
receiving CPX-351 had a lower disease burden